 |
|
|
| |
An Open-Label Study to Evaluate the Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults with Chronic HCV Genotype 4 Infection in Egypt (AGATE-II)
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Wahid Doss1, Gamal Esmat2, Roula B Qaqish3, Imam Waked4, Gamal Shiha5, Ayman Yosry2, Jennifer King3, Coleen Hall3, Niloufar Mobashery3
1National Hepatology & Tropical Medicine Research Institute, Cairo, Egypt; 2Cairo University, Cairo, Egypt; 3AbbVie Inc., North Chicago, Illinois, USA; 4National Liver Institute, Menoufiya, Egypt; 5Egyptian Liver Research Institute and Hospital (ELRIAH), Dakahliah, Egypt
|
| |
|
|
|
|
|
